CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or

CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 06, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca, has progressed into the Patent…

Blackstone puts $250M into Anagram to tackle cystic fibrosis complication

Blackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the number of ...